T he characteristics used to classify tumours, such as the appearance of cancer cells under a microscope, usually reflect the type of cell from which the cancer originated. Yet sometimes the same type of cell can give rise to cancers that are substantially different in appearance and prognosis. The mechanisms that dictate this type of diversity in cancer development are mainly unknown. Seehawer et al. 1 reveal on page 69 that the same type of cell can give rise to different types of cancer depending on the sort of cell death that occurs nearby in the tumour microenviron ment. This suggests that nearby injury or dam age can affect the identity of a cancer.
Human tumour samples are classified in the clinic using a microscopebased technique called histology to assess the shape and form of tumour cells. A prognosis is determined and treatment decisions are made on the basis of this classification. This approach assumes that cancer cells' appearance reflects that of their cell of origin.
A key mechanism that enables tumour cells to retain the characteristics of their founder cell is the formation of heritable types of altera tion, known as epigenetic changes. These are chemical modifications, such as the attach ment of methyl groups, that are made to DNA and to the histone proteins that associate with it to form chromatin. Epigenetic modifica tions affect chromatin structure and can have longterm effects on gene expression without changing the genome sequence.
Differences between particular subtypes of tumour can arise if tumours originate from different types of cell residing in normal tis sue 2, 3 . But in some cases, the same type of cell can give rise to two different tumour sub types. One explanation for such a divergence is the presence of mutations that affect cellular appearance 4 . Yet the mechanisms that under lie diversity in cancer subtype are mainly unknown, which is important medically because tumour identity is linked to prognosis and treatment options.
Liver cancer is the secondhighest cause of cancer mortality globally 5 , and two common histologically distinguishable subtypes are called hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).
Originally, it was thought that differentiated hepatocytes, the main type of cell in the liver, give rise to HCC, and that bileduct cells (also called cholangiocytes) in the liver give rise to ICC. Yet studies in mice indicate that both HCC and ICC can arise from hepatocytes 6, 7 . But how can the same type of cell form two different tumour subtypes that have striking differences in form and progression?
Seehawer and colleagues made a fortuitous discovery when generating liver cancer in mice by the in vivo delivery of identi cal cancerpromoting genes. The animals developed either HCC or ICC, depending on whether the genedelivery technique was tail vein injection or electroporation, respectively (Fig. 1) . The authors recognized that investi gating this observation might shed light on a fundamental aspect of cancer development.
Using lineagetracing experiments to track the cells of origin for the tumours that arose, the authors found that HCCs and ICCs were both derived from cells called differentiated hepatocytes. Seehawer et al. did not find any striking differences in the mutational pro files of the proteincoding DNA sequence in HCCs and ICCs. The authors sampled liver tis sue immediately after gene delivery to assess whether the genedelivery method caused any differences in the tumour microenviron ment. Tailvein injection, the genetransfer method associated with HCC formation, caused some hepatocytes in the surrounding region of tumour development to undergo a type of cell death called apoptosis, whereas electro poration, associated with ICC forma tion, caused the neighbouring cells to undergo a type of cell death termed necroptosis.
The experimental introduction of cancer promoting genes into hepatocytes usually generates HCC as the default, rather than ICC. The authors therefore investigated whether necroptosis influenced ICC formation. They found that if necroptosis was induced after apoptosis occurred in their experimental set up, it resulted in ICC. Conversely, the suppres sion of necroptosis, either by drugs or by the presence of certain mutations, favoured HCC formation. These results are consistent with a model in which necroptosis favours the forma tion of ICC rather than HCC, and suggest that a switch in cancer development towards ICC in the livers of mice that have chronic liver disease is not due to the proliferation of bile duct cells, as was previously thought, but that these structures arise from hepatocytes, and that this therefore constitutes a form of meta plasia. Interestingly, a similar pattern of growth of bileductlike cells is often observed in human livers 8, 9 . Although this is not usually considered as a form of metaplasia, it is associ ated with an increase in the risk of liver can cer 9 . Could the switch between HCC and ICC in mice be similar to the process that occurs in liver metaplasia in humans? If it is, Seehawer and colleagues' work might provide insight into how metaplasia increases cancer risk. ■ requires a signalling input that is influenced by necroptosis.
Eli Pikarsky is at the Lautenberg
Necroptosis is a more inflammatory form of cell death than apoptosis. The authors analysed immunesignalling molecules called cytokines in the livers of mice given the cancerinducing treatments, and observed differences in the cytokine pattern depending on whether HCC or ICC developed. For example, they noted an increase in the expression of cytokines AIMP1, CCL4 and CXCL13 associated with ICC, compared with their levels in HCC. This raised the question of whether necrop tosisassociated inflammation might induce epi genetic changes in hepatocytes that are poised to become cancer cells. The authors found differences in chromatin structure in selected regions of the genome between the two cancer subtypes, although when and how these differences arose is unknown.
Seehawer and colleagues also observed that the transcriptionfactor protein TBX3 was more highly expressed in HCC than in ICC, whereas the transcription factor PRDM5 had the opposite pattern of higher expression in ICC than in HCC. These expression differences were associated with epigenetic differences in the chromatin structure of the genes encoding these proteins. Remarkably, when the authors analysed samples of human HCC or ICC, they also observed the same pattern of higher TBX3 expression in HCC than in ICC, and higher PRDM5 expression in ICC than in HCC.
Altogether, the evidence suggests that the celldeath conditions prevailing in the liver at the earliest stages of tumour formation might account for the formation of these two differ ent tumour subtypes. Early events in tumour formation are long over by the time a biopsy sample is taken from a human liver; this mouse study could help to illuminate key events that shape the initial steps of tumour formation and result in different cancer identities.
The study provides strong evidence that the tumour microenvironment provides yettobe identified signals that can impart longlasting changes to the fate of cells poised to form cancer cells. Perhaps cytokines might be the drivers of this cancersubtype switch. If so, the release of such cytokines because of tissue damage or disease might shape the identity of a cancer that is starting to form nearby.
In Seehawer and colleagues' experimental system, the cancersubtype switch occurred after the acquisition of cancerpromoting genes. However, in human cancers, a differ ent sequence of events is often noted that is thought to occur before the acquisition of cancerpromoting genetic changes. In this scenario, an increased risk of cancer is asso ciated with a process called metaplasia, in which one type of differentiated cell reversibly switches to a different type of differentiated cell. How a predisposition to malignancy arises because of metaplasia is unknown.
It has been reported 8 Narcolepsy affects around 1 in 2,000 people 2 . The symptoms usually begin in adolescence or early adulthood, and include daytime sleepi ness and, in some cases, cataplexy -sudden muscle weakness during wakefulness that causes falls. A small population of neurons in the brain produces a protein called hypo cretin, which controls sleep-wake cycles 3 , and narcolepsylike symptoms occur in ani mals that have defects in genes required for the production of or response to hypocretin 4 . Narcolepsy type 2 is associated with daytime sleepiness, and this can progress to narcolepsy type 1, which is characterized by sleepiness and cataplexy. People with narcolepsy type 1 have abnormally low numbers of hypocretin producing neurons 5 . Hypocretin levels in the cerebrospinal fluid that bathes the brain and spinal cord can be measured to help diagnose 6 , but it is found in only 15-30% of the general population, depending on ethnicity 8, 9 . More over, previous reports 10,11 suggest that antibodies targeting neuronal proteins are present at a higher than usual frequency in people with narcolepsy.
Latorre and colleagues used various techniques to identify human T cells that recognize specific antigens. The authors tested whether T cells that recognize antigens from hypocretin were present in blood samples
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Put to sleep by immune cells
The sleep disorder narcolepsy is linked to immune-system genes and is caused by the loss of neurons that express the protein hypocretin. 
